JP2005089385A - Lipoxygenase inhibitor - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a highly safe lipoxygenase inhibitor obtained by effectively utilizing a plant of Ixeris dentata having bioactivities, easily available as a component derived from a plant, hardly causing side effects on a living body, and applicable to an agent for preventing allergy symptom, cardiovascular disease or growth of the hair, an agent for regulating depilation, a composition for cosmetics, or the like; and to provide a functional food or food material for inhibiting the lipoxygenase to enable these diseases to be ameliorated. <P>SOLUTION: This lipoxygenase inhibitor contains the Ixeris dentata and/or a treated product thereof as an active ingredient. The treated product is preferably a fermentation-treated product of the Ixeris dentata. The fermentation-treated product of the Ixeris dentata is preferably obtained by fermenting the Ixeris dentata until the content of luteolin is ≥100×10<SP>-5</SP>wt.% preferably by using a lactic acid bacterium, the lactic acid bacterium and a yeast, the lactic acid bacterium and Bacillus subtilis, or the lactic acid bacterium, the yeast and the Bacillus subtilis. <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

  The present invention relates to a lipoxygenase inhibitor using a physiologically active substance derived from a Japanese leek plant growing in Okinawa, and a functional food or food material for lipoxygenase inhibition containing these as active ingredients.

  Conventionally, excellent natural resources containing physiologically active substances have been developed for plants native to Okinawa. For example, an antioxidant plant fiber using plant fibers that are not used as food materials or processed foods thereof (see, for example, Patent Document 1), 1 selected from the group consisting of ghetto, red-crowned wrinkle, hiramon lemon, damselfly, and strelitzia Substances for inhibiting α-amylase activity (for example, refer to Patent Document 2) characterized by using as an active ingredient a dry powder or extract of more than one kind of plant have also been reported. Ixeris dentata is a perennial plant belonging to the genus Asteraceae. It contains a white latex with a bitter taste on the leaves and stems, and is vegetated normally in mountains and fields, and is often found in Okinawa. Nigana contains a component having a function (ACE activity inhibitory function) that suppresses the conversion of angiothecin I, which is a peptide present in blood, to angiophysin II by the action of an enzyme, thereby exhibiting an effect of suppressing an increase in blood pressure. (For example, refer to Patent Document 3).

  On the other hand, arachidonic acid is a long-chain highly unsaturated fatty acid that exists as a component of cell membranes in vivo, and is released from phospholipids by the action of phospholipase when stimulated. Oxygen molecules are added to liberated arachidonic acid by the action of lipoxygenase. For example, 15-hydroperoxyacid (15-HPETE) oxygenated to carbon 15 by 15-lipoxygenase is carbon 12 by 12-lipoxygenase. 12-hydroperoxy-5,8,10,14-eicosatetraenoic acid (12-HPETE) was produced in the same manner, and 5-hydroperoxy-oxygenated to carbon at the 5-position by 5-lipoxygenase as well. 6,8,10,14-Eicosatetraenoic acid (5-HPETE) is produced. These are converted into substances such as allergic diseases, inflammation, leukotrienes (LT) involved in asthma, thromboxane (TX) involved in thrombus formation, etc., and cardiovascular diseases such as arteriosclerosis, allergic Induces disease, inflammation, and cancer translocation.

By inhibiting the activity of lipoxygenase having such an action, it is possible to treat, improve or prevent inflammation, allergic diseases, cardiovascular diseases, cancer translocation, etc. induced by the above-mentioned riboxygenase. Inhibitors of lipoxygenase activity are known. For example, a lipid peroxide production inhibitor containing an aminocoumaran derivative having a lipid peroxide production inhibitory action, a lipoxygenase and HHT production inhibitory / suppressive action (see, for example, Patent Document 4), or a 5-lipoxygenase containing a quinone derivative as an active ingredient Inhibitors, thromboxane synthase inhibitors (for example, see Patent Document 5), and 5-riboxygenase inhibitors containing bicyclic ether derivatives having a specific substituent having a heterocyclic ring or the like (for example, see Patent Document 6) ), Lipoxygenase inhibitors for regulating hair and / or hair growth using diallyl sulfide, di- (1-propenyl) sulfide and the like have been reported (for example, see Patent Document 7). In addition, since the polyphenols luteolin and chrysoeriol contained in the alcohol extract of sesame seeds have lipoxygenase inhibitory activity, a lipoxygenase inhibitor comprising an alcohol extract of sesame seeds containing luteolin, chrysoeriol, etc. as an active ingredient ( For example, see Patent Document 8).
JP 2002-204673 A JP 2001-333733 A JP-A-6-225723 Japanese Patent Laid-Open No. 5-140142 JP-A-5-78321 JP 9-504775 gazette JP 10-36235 A Japanese Patent Laid-Open No. 10-298098

  An object of the present invention is to make effective use of a plant having a physiological activity, and can be easily obtained as a plant-derived component, has low side effects on the living body, is highly safe, and has inflammation, allergic symptoms, cardiovascular disease, or hair. An object of the present invention is to provide a lipoxygenase inhibitor that can be applied to a growth inhibitory or hair removal regulator, a cosmetic composition, or the like, or a lipoxygenase-inhibiting functional food or food material that can improve such diseases.

  The inventors of the present invention have conducted research on the physiological activity for the purpose of effective utilization of the Japanese algae plants growing in Okinawa. As a result, they have found that the extract of Japanese algae leaves has an excellent lipoxygenase inhibitory activity. As a result, the fermented product of Japanese red crab fermented with lactic acid bacteria and the like has an increased content of luteolin and has an excellent lipoxygenase inhibitory activity. Based on these findings, the present invention has been completed.

That is, the present invention relates to a lipoxygenase inhibitor characterized by comprising Japanese red crab (Ixeris dentata) and / or its treated product as an active ingredient, preferably, the treated product is a fermented product of Japanese char. The lipoxygenase inhibitor according to claim 1 (claim 2) or a fermented processed product of nigana is a fermented processed product fermented to a luteolin content of 100 x 10 ^-5 wt% or more. The lipoxygenase inhibitor according to Item 2 (Claim 3) or a fermented product is a fermented product of lactic acid bacteria, lactic acid bacteria and yeast, lactic acid bacteria and Bacillus subtilis, or lactic acid bacteria, yeast and Bacillus subtilis. The lipoxygenase inhibitor according to 2 or 3 (claim 4).

  The present invention also relates to a functional food or food material for inhibiting lipoxygenase, characterized by comprising the lipoxygenase inhibitor according to any one of claims 1 to 4 as an active ingredient.

  The prophylactic / therapeutic agent for inflammatory diseases according to the present invention is to prepare a prophylactic / therapeutic agent for inflammatory diseases that can be easily obtained as a plant-derived component and that has low side effects on the living body and is highly safe, by effectively utilizing the Japanese algae plant. Thus, a functional food or food material for prevention / amelioration of anti-inflammatory diseases can be easily obtained.

  The lipoxygenase inhibitor of the present invention is not particularly limited as long as it contains nigana (Ixeris dentata) and / or a processed product thereof as an active ingredient. The cruciferous plant used in the lipoxygenase inhibitor of the present invention is a plant belonging to the family Asteraceae, and the use site may be an underground part such as a root or an above-ground part such as a stem, a leaf, or a flower. , A mixture of two or more of these, or a whole plant. Of these, leaves are particularly preferred.

  Examples of the treatment in the processed product of the Japanese algae include pulverization treatment, cutting treatment, drying treatment, extraction treatment, roasting treatment, ultrasonic homogenization treatment, freezing treatment, heat treatment, enzyme treatment, fermentation treatment, and the like. Two or more processes may be combined. For example, a treatment for pulverizing to a particle size of 3 mm or less, preferably 0.5 to 1.0 mm, is preferable as the pulverization treatment of the negative. By setting the particle size to 3 mm or less, the active ingredient can be easily extracted, and if the particle size is in the range of 0.5 to 1.0 mm, this effect can be obtained more remarkably. Moreover, although the living body of a plant may be pulverized as it is, a pulverization process may be performed on a processed product that has been previously subjected to a cutting process, a drying process, a freezing process, or the like. Conversely, the pulverized product obtained by pulverizing the plant can be subjected to a drying process such as an air drying process at room temperature, a heat drying process at around 40 to 60 ° C., or a sun drying process. Furthermore, an extraction process can also be performed with respect to the dry-processed material after a grinding process, and the ground material after a dry process. As the treated product of the present invention, it is possible to advantageously use a lyophilized product obtained by pulverizing a raw leaf or dried leaf obtained by such an extraction treatment as it is or lyophilized after removing the solvent. In addition, if necessary, a plurality of these extracts can be mixed, or a mixture obtained by mixing with a solvent can be used.

  Examples of the solvent used in the extraction treatment include lower monohydric alcohols such as water, methyl alcohol, and ethyl alcohol, liquid polyhydric alcohols such as glycerin, propylene glycol, and 1,3-butylene glycol, and non-hexane such as hexane. One kind or two or more kinds of polar solvents can be used. As a preferable extraction method, for example, methyl alcohol or ethyl alcohol having a water concentration of 0 to 100% by volume is used, and extraction is performed at 0 to 80 ° C. for 30 minutes to 5 days, preferably using an ethyl alcohol aqueous solution at room temperature for 24 hours. And then filtering.

Furthermore, as a process in a processed product of a Japanese algae, a fermentation process can be mentioned as a preferable process. The fermentation treatment is preferably a fermentation treatment in which fermentation is performed until the luteolin content is 100 × 10 ⁻⁵ wt% or more. In such a fermentation process, it is possible to use a pulverized product obtained by subjecting a living body or a dried product to the above-described pulverization process as a substrate, so that a sufficient contact area with the fermenting bacteria can be secured, and the fermentation proceeds effectively. This is preferable.

  As the microorganism used for the fermentation treatment, lactic acid bacteria, yeast, Bacillus subtilis can be used, and these can be used alone or in combination of two or more, but lactic acid bacteria alone, lactic acid bacteria and yeast, lactic acid bacteria and Bacillus subtilis, Or the combination of lactic acid bacteria, yeast, and Bacillus subtilis is preferable.

Examples of the lactic acid bacteria used in the fermentation treatment include Streptococcus, Lactobacillus, Leuconostoc, Pediococcus, Bifidobacterium, and Tetrageno. Bacteria belonging to any of the genera Tetragenococcus are preferred, and Lactobacillus is particularly preferred. The bacterium belonging to the genus Streptococcus is preferably Streptococcus thermophilus (S. thermophilus), and specific examples include Streptococcus thermophilus IFO13957 strain. Moreover, as a bacterium belonging to the genus Lactobacillus, any of Lactobacillus plantarim (L. plantrum), Lactobacillus delbruckii (L. delbruckii), Lactobacillus pentosus (L. pentosus) or Lactobacillus casei (L. casei) Among these bacteria, Lactobacillus plantarim is particularly preferable. Specific examples of such Lactobacillus plantarim include IFO14712 and IFO14713 strains, Lactobacillus delbriqui as IFO13953 strain, Lactobacillus pentosus as IFO12011 strain, and Lactobacillus casei as IFO15883 strain. Moreover, as a microbe which belongs to Tetragenococcus genus, it is preferable that it is Tetrageno halophyllus (T. halophilus), and tetrageno halophyllus IFO12172 strain can be illustrated concretely. These lactic acid bacteria are preferably used in an amount of usually 10 ³ to 10 ⁷ , especially 10 ⁶ to 10 ⁷ , per 1 g of dried dry matter of the plant.

Moreover, the yeast used for the said fermentation process is mainly added for the improvement of fragrance, As this yeast, the microbe which belongs to Candida (Candida) or Saccharomyces (Saccharomyces) is preferable. As such a bacterium belonging to the genus Candida, Candida versatilis is preferable, and IFO10038 strain can be specifically exemplified as Candida versatilis. The bacterium belonging to the genus Saccharomyces is preferably S. cerevisiae, and IFO0555 strain can be specifically exemplified as Saccharomyces cerevisiae. It is preferable to use 10 ³ to 10 ⁷ , especially 10 ⁶ to 10 ^{7 of} these yeasts per 1 g of dry matter of the Japanese algae plant.

Furthermore, as a Bacillus subtilis used in the said fermentation process, a Bacillus subtilis (B. subtilis) IFO3013 strain can be illustrated specifically. These Bacillus subtilis are preferably used in an amount of usually 10 ³ to 10 ⁷ , particularly 10 ⁶ to 10 ⁷ , per 1 g of dried dry matter of the Japanese algae plant.

  In the above fermentation treatment, the microorganism group preferably used is a microorganism group including lactic acid bacteria, yeast and Bacillus subtilis, and among these microorganism groups, a mixed bacteria of Lactobacillus plantarim, Streptococcus thermophilus, Bacillus subtilis. It is preferable to use the same number as the number of bacteria with respect to the dry matter of the Japanese algae plant. By using the bacteria in such a combination of the number of bacteria, the fermentation time can be shortened, and thus the propagation of various bacteria can be suppressed.

In the fermentation treatment, it is preferable to add 2 to 10 parts by weight, particularly about 5 parts by weight, of water to 1 part by weight of dry matter in order to promote the progress of fermentation to the ground crushed product. The above-mentioned bacteria or fungal group is added to the pulverized product. It is preferable to add 1 to 10% by weight of each fungus group after culturing each fungus before mixing to the medium and adding to the medium in advance. The fermentation is performed at a temperature of 20 to 50 ° C., preferably 40 ° C., and the fermentation time is such that the content of luteolin in the nigana is 100 × 10 ⁻⁵ wt% or more, preferably 150 × 10 ⁻⁵ wt% or more. Furthermore, it can be appropriately selected depending on the progress of fermentation under conditions such as pH and the number of bacteria, and preference. For example, if the pH is 4 to 5 and the number of bacteria is 10 ⁶ or more, it can be about 72 hours. . At the time of fermentation treatment, aeration and deoxygenation treatment can be performed as necessary, but after the deoxygenation treatment, fermentation can be performed in stationary culture. The fermentation format is preferably solid culture rather than liquid culture.

  In such a fermentation treatment, carbohydrates and proteins can be added as an agent for fermenting bacteria. The carbohydrate as the assimilating agent is preferably a commercially available sugar such as glucose, sucrose, molasses, etc., and the amount of these added is preferably 1 to 10% by weight per medium, particularly around 3% by weight. The protein as an assimilating agent is preferably rice bran, bran or the like, and the addition amount thereof is preferably 1 to 5% by weight per medium. These assimilating agents may be used alone or in combination of two or more.

  After completion of fermentation, drying is preferably performed by a dryer so that the moisture value is 10% by weight or less. As a drying method, heat drying or freeze drying can be used. In the case of heat drying, the product temperature is 100 ° C. It is preferable that the following is performed because the deactivation of the physiologically active ingredient can be prevented. After drying, if necessary, sterilization is carried out by a known method such as heating to obtain a fermented nibbana that can be suitably used as a lipoxygenase activity inhibitor.

As for the fermented processed product of Japanese abbaca obtained by the above fermentation treatment, the luteolin content is 100 × 10 ⁻⁵ wt% or more, preferably 150 × 10 ⁻⁵ wt% or more, and as shown in FIG. Whereas the content of luteolin in Japanese algae is about 7.2 × 10 ⁻⁵ wt% as measured by high performance liquid chromatography of the pulverized dried Japanese algae methanol extract, fermentation treatment such as Lactobacillus plantarim, Streptococcus thermophilus and Bacillus subtilis mixed bacteria are obtained by adding 0.1 g and 3 g of water to 1 g of Japanese lobster leaves crushed to 0.5 to 1.0 mm, followed by fermentation at 40 ° C. for 72 hours. The luteolin content of the processed fermented nigana increases remarkably to around 173.40 × 10 ⁻⁵ wt%. This is because luteolin glycosides contained in Japanese algae that are not subjected to fermentation treatment are significantly increased by hydrolysis by the fermenting bacteria. Since luteolin is a kind of aglycone and has a remarkable antioxidant activity, the antioxidant activity caused by luteolin is increased and the lipoxygenase inhibitory activity is increased in the fermented product of Japanese algae.

  The lipoxygenase inhibitor of the present invention, which comprises the above Japanese ligan and / or processed product thereof as an active ingredient, is obtained by converting lipochigenase such as 12-lipoxygenase or 5-lipoxygenase from arachidonic acid to 12-hydroperoxy-5,8,10,14-eicosa. It inhibits the production of arachidonic acid metabolites such as tetraenoic acid (12-HPETE) and 5-hydroperoxy-6,8,10,14-eicosatetraenoic acid (5-HPETE). Such a lipoxygenase inhibitor of the present invention is effective for treatment, amelioration, and prevention of diseases caused by arachidonic acid metabolites produced by lipoxygenase. For example, inflammation, allergic symptoms, cardiovascular diseases, or hair growth It can be applied to pharmaceuticals such as inhibitors or hair removal regulators, quasi-drugs, cosmetic compositions, functional foods or food materials.

  The lipoxygenase inhibitor of the present invention can be used as a preparation for internal use in combination with a known pharmaceutical carrier or as an external preparation. As a pharmaceutical carrier in such a preparation for internal use, a pharmaceutically acceptable liquid or solid carrier can be applied using the lipoxygenase inhibitor nigana of the present invention and / or a processed product thereof as an active ingredient. The lipoxygenase inhibitor of the invention includes a solvent, a dispersant, an emulsifier, a buffer, a stabilizer, an excipient, a binder, a disintegrant, a lubricant, a diluent, a pH buffer, a solubilizing agent, if necessary. An isotonic agent or the like can be added to prepare a solid preparation such as a tablet, granule, powder, powder or capsule, or a liquid preparation such as a normal solution, suspension or emulsion. These preparations can be administered orally or parenterally. That is, it can be administered orally in commonly used dosage forms, such as powders, granules, capsules, syrups, suspensions, etc., or, for example, in dosage forms such as solutions, emulsions, suspensions, etc. These can be administered parenterally in the form of injections or can be administered intranasally in the form of sprays. The dose can be appropriately selected depending on the type of disease, the weight of the patient, the dosage form, and the like. The dosage of such a preparation is appropriately set according to the preparation form, administration method, purpose of use and age, weight, and symptoms of the patient applied thereto, and is not constant, but in general, the active ingredient contained in the preparation The amount is 10 μg to 200 mg / kg per adult day. Since the dose varies depending on various conditions, an amount smaller than the above dose may be sufficient or may be necessary beyond the range. The lipoxygenase inhibitor of the present invention can be administered orally as it is, or can be added to any food or drink as a food or food material described later and ingested on a daily basis. In addition, when the lipoxygenase inhibitor of the present invention is used as an external preparation, it can be kneaded with ethanol or the like and an emulsion, or a Japanese extract with petrolatum or the like to make an ointment.

  As a method for preparing the lipoxygenase inhibitor of the present invention, the above-mentioned Japanese algae, a processed product such as a fermented product thereof, a freeze-dried product obtained by freeze-drying an extract with hot water or ethanol, etc., are powdered with a mixer or the like, Illustrate in specific examples such as granulating, encapsulating, tableting the obtained powder, preparing a solution by dissolving, suspending, dispersing, etc. in a solvent, or applying the extract as it is Can do.

  When the lipoxygenase inhibitor of the present invention is applied to a cosmetic composition or quasi-drug, it may be in any form, and the preparation obtained by the above-described adjustment method can be used as a lotion, lotion, liquid cream, cream , Emulsions, packs, oils, soaps (including medicinal soaps), prior application materials, bath preparations, shampoos, rinses, sprays, ointments, bandages, sanitary cotton, wet tissue, and the like.

  The lipoxygenase-inhibiting functional food or food material of the present invention containing nigarana and / or a processed product thereof as an active ingredient is one or two or more selected from nigana and / or a processed product thereof as a part of the raw material for food and drink. It can be obtained by use, or by adding and blending after the production process or production. In order to suppress the change of arachidonic acid to hydroperoxyarachidonic acid by inhibiting the action of lipoxygenase as described above, it is desirable to ingest a substance having a moderate lipoxygenase inhibitory effect every day. The functional food or food material for inhibiting lipoxygenase containing the lipoxygenase inhibitor of the present invention is desirably taken from a food or drink, and is extremely useful in that respect. The functional food or food material for inhibiting lipoxygenase of the present invention may be in any form, such as yogurt, drink yogurt, juice, milk, soy milk, liquor, coffee, tea, sencha, oolong tea, sports drink, etc. Various beverages, baked confectionery such as pudding, cookies, bread, cakes, jelly, rice crackers, Japanese confectionery such as sheep candy, bread and confectionery such as frozen confectionery, chewing gum, noodles such as udon and soba, kamaboko, ham, fish sausage Fish paste products such as miso, soy sauce, cooking oil, margarine, lard, butter, dressing, mayonnaise, sweeteners, dairy products such as cheese, butter, tofu, konjac, other boiled fish, dumplings, croquettes It can be blended into various side dishes such as salads and used as food. A compounding quantity is not specifically limited, It can select suitably with foodstuffs.

  EXAMPLES Hereinafter, although an Example demonstrates this invention more concretely, the technical scope of this invention is not limited to these illustrations.

[Preparation of fermented nibbana]
30 g of dried Japanese algae leaves were pulverized to a particle size of 0.1 to 3 mm and placed in a container. 150 g of water, 0.9 g of molasses, and 0.9 g of rice bran were added to the container containing the nigana. After culturing each strain of Lactobacillus plantarim (IFO14712 strain, IFO14713 strain), Streptococcus thermophilus (IFO13957 strain), and Bacillus subtilis (IFO3013 strain) in a container containing the pulverized Japanese algae, the number of bacteria was 1: 1. The mixture was mixed at a ratio of 1: 10% by weight with respect to the weight of the nigana, the container was sealed, and fermentation was performed by stationary culture. The fermentation temperature was 40 ° C. and the fermentation time was 72 hours. Then, after drying at 60 degreeC until the moisture value became 10 weight% or less with a dryer, the sterilization process (130 degreeC steam, 5 to 15 second) was performed, and 31 g of fermented Japanese charcoal was obtained.

[Sample preparation]
(i) 0.1 to 3 mm crushed and dried leaves of Japanese agar, fermented Japanese agar obtained in Example 1, 10 ml of 80% ethanol per 1 g each, extracted by standing for 12 hours, filtered, and then 80% ethanol was added to the residue. 10 ml was added and extracted in the same manner. Thereafter, the filtrate was adjusted to 20 mg / ml with dimethyl sulfoxide solvent, and each 80% ethanol extract was obtained.
(ii) 0.1 g of crushed and dried leaves of nibbana and 1 g of fermented nibbana obtained in Example 1 were added 25 ml of hot water at 80 ° C., extracted by standing for 20 minutes, filtered and the same as the residue The hot water was added and extracted. These filtrates were fixed to 50 ml to obtain respective hot water extracts.

[Measurement of luteolin content]
The content of luteolin was measured for 0.1 to 3 mm pulverized and dried leaves of Japanese algae and fermented Japanese algae obtained in Example 1. 100 ml of methanol was added to 2 g of sample, reflux extraction for 1 hour was performed twice, and the extract was made up to a constant volume of 250 ml with methanol, and measured by high performance liquid chromatography (HPLC) (manufactured by SHIMADZU). For high performance liquid chromatography (HPLC), the column is YMC-Pack. AM-312 (ODS), methanol: water = 50: 50 (adjusted to pH 2.5 with trifluoroacetic acid), flow rate 1 ml / min. Measured at 365 nm.

From the results, the content of 7.2 × 10 ⁻⁵ wt% before fermentation increased to 173.4 × 10 ⁻⁵ wt% in fermented Japanese algae, and the content of luteolin was significantly increased by fermentation. I understood.

[Evaluation of lipoxygenase inhibitory activity]
After adding 10 μl of the sample obtained in Example 2 to 50 μl of distilled water, 20 μl of 0.5 M Tris-HCl buffer (containing pH 8.0, 10 mM Ca +, ATP) and 10 μl of phosphatidylcholine (manufactured by Sigma), 250 unit human 5- 10 μl of lipoxygenase (CAYMAN) was added and mixed at the same time, and the mixture was heated at 30 ° C. for 5 minutes. Thereafter, 2 μl of 50 mM arachidonic acid (manufactured by Sigma) was added in ice, followed by heating at 30 ° C. for 10 minutes. After stopping the reaction by adding 300 μl of ice-cold methanol at −20 ° C., 1 μl of 1M acetic acid solution was added. This was centrifuged at 4 ° C. and 10,000 rpm for 10 minutes, and the amount of produced 5-hydroperoxyeicosatetraenoic acid (5-HPETE) present in the supernatant was measured using a high performance liquid chromatograph (Shimadzu). The measurement was performed under the conditions described below. The measured values are shown in Table 1. The 5-HPTEE production rate in the sample when the amount of 5-HPTEE produced in the control with no sample added was taken as 100 was determined. The results are shown in Table 1 and FIG.
Conditions Column: Develosil ODS-60-5 (4.6 caliber × 150)
Mobile phase: methanol: water: acetic acid = 80: 20: 0.01
Flow rate: 0.8 ml / min Column temperature: Room temperature UV wavelength: 233 nm (Range 0.04 ×, A ++. 16 ×)

  From the results, the presence of Japanese algae, a fermented product of the Japanese algae, suppressed the production of 5-HPETE, an arachidonic acid metabolite, and both the negative and the fermented product of the Japanese algae suppressed the action of 5-lipoxygenase, It is clear that it has lipoxygenase inhibitory activity. In particular, it is clear that the fermented product of Japanese algae has a remarkable 5-lipoxygenase inhibitory activity.

It is a figure which shows the content of luteolin in Japanese algae and fermentation Japanese algae. It is a figure which shows the 5-HPTEE production rate in the presence of Japanese algae and fermentation Japanese algae.

Claims (5)

A lipoxygenase inhibitor characterized by comprising Ixeris dentata and / or a processed product thereof as an active ingredient. The lipoxygenase inhibitor according to claim 1, wherein the processed product is a fermented product of Japanese algae. The lipoxygenase inhibitor according to claim 2, wherein the fermented product of Japanese algae is a fermented product that has been fermented until the luteolin content reaches 100 × 10 ⁻⁵ wt% or more. The lipoxygenase inhibitor according to claim 2 or 3, wherein the fermented product is a fermented product of lactic acid bacteria, lactic acid bacteria and yeast, lactic acid bacteria and Bacillus subtilis, or lactic acid bacteria, yeast and Bacillus subtilis. A functional food or food material for inhibiting lipoxygenase, comprising the lipoxygenase inhibitor according to any one of claims 1 to 4 as an active ingredient.

Images